Across TCGA pan-cancer cohorts, BRCC3 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated BRCC3 data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher BRCC3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated BRCC3 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BRCA, SKCM, and LAML are the cancer types where BRCC3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.733	0.924	<.001	24	view →
SKCM	OS	Median	III,IV	0.230	0.721	.004	16	view →
LAML	DFS	Median	All	0.112	0.582	.010	12	view →
UCEC	DFS	Median	III,IV	1.000	0.542	.047	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: BRCC3 tumor-vs-normal RNA expression · all BRCC3 data types